Novo Nordisk Reports Q3 2026 Results and Raises Full-Year Guidance

Novo Nordisk reported third-quarter 2026 sales of 79.19 billion Danish kroner, up 6% year over year, with the recently launched Wegovy pill contributing 5.39 billion kroner. Citing strong uptake of its GLP-1 products, the company raised its full-year 2026 guidance for sales and adjusted operating profit growth to -2% to 2% at constant exchange rates, an improvement of about three percentage points from its previous outlook.